Oct 1992;87(10):1424-1428
The Ozempic label warns that concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia, and reports documented symptomatic hypoglycemia in 17.3% and 24.4% of patients when Ozempic 0.5 mg and 1 mg respectively were coadministered with a sulfonylurea
This matters even more when heart or weight concerns are part of the picture, where the whole diet can influence outcomes
When appetite drops dramatically, many people naturally reduce protein intake, which can lead to muscle loss alongside fat loss
Moreover, the injection has been praised for its non-invasive nature, allowing people to achieve beautiful results without the downtime associated with more invasive procedures
These obstacles can affect reproducibility and slow mechanistic discovery